What completed clinical trials has Neurocept reported for major depressive disorder through 2023?

1. Sharp contrast: public records show a Neurocept trial listing, but no published results that confirm completion or outcomes

ClinicalTrials.gov includes a study entry titled “Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder,” which links the compound to Neurocept in the record summary; however, the entry in the provided analysis does not furnish conclusive evidence of posted results, peer‑reviewed publications, or corporate press releases reporting a completed trial and its outcomes through 2023. The existence of a registry entry is meaningful because it shows intent and protocol-level planning, but a listing alone does not equal a completed, reported trial with publicly available data, and the supplied notes explicitly call out the absence of detailed results ^[1].

2. Major published Phase 2 data belong to Neumora/BlackThorn, not Neurocept — a common source of confusion

Multiple supplied analyses describe a randomized, double‑blind Phase 2 trial of navacaprant (NMRA-140) that found statistically significant reductions in depressive symptoms and anhedonia for certain subgroups; those analyses attribute the work to BlackThorn Therapeutics and later Neumora Therapeutics after acquisition, with trial dates through mid‑2022 and publication or poster reporting in late 2023. Those results are real and notable, but they are explicitly tied to Neumora/BlackThorn rather than Neurocept, and conflating the sponsors would misattribute the evidence ^{[2] [3]}.

3. Cross‑checking the record: what the provided sources agree on and where they diverge

The sources consistently agree that navacaprant advanced through a Phase 2 program showing some positive signals and that Neumora intended Phase 3 work ^[2]. The divergence arises around Neurocept: one analysis flags a ClinicalTrials.gov entry that links Neurocept to an NMRA‑335140 study ^[1], while several summaries explicitly state Neurocept is not mentioned and instead spotlight Neumora’s navacaprant program ^{[4] [3] [5]}. The practical takeaway is that the strongest, publicly reported MDD trial evidence through 2023 belongs to Neumora/BlackThorn; the Neurocept association rests on a registry entry absent corroborating publications or press statements ^{[1] [5]}.

4. Why the distinction matters: scientific credibility and corporate signaling are not interchangeable

A completed, peer‑reviewed trial with full data is the gold standard for establishing efficacy and safety; sponsor names in registry entries, corporate press releases, and conference posters must be cross‑validated to avoid misattribution. Attributing a completed MDD trial to Neurocept based solely on a registry listing would overstate the public evidence because the provided materials lack trial results, publications, or company reports from Neurocept detailing completion and outcomes for NMRA‑335140 through 2023 ^[1]. By contrast, the navacaprant data from BlackThorn/Neumora include trial-level results presented in posters and company announcements, which are citable evidence of completion and outcome reporting ^[2].

5. Bottom line and recommended next steps for verification

The accurate statement based on the supplied materials is that Neurocept has a ClinicalTrials.gov record for an NMRA‑335140 study in MDD, but there is no corroborating published completion report or company disclosure through 2023 to confirm a completed, reported trial attributable to Neurocept; major completed Phase 2 results in MDD through 2023 instead involve navacaprant under BlackThorn/Neumora ^{[1] [2]}. To resolve the remaining uncertainty, consult the ClinicalTrials.gov record directly for status and results postings, search Neurocept’s 2021–2023 corporate filings or press releases, and look for peer‑reviewed publications or conference abstracts that explicitly list Neurocept as sponsor or author. ^{[1] [2]}